The United States and United Kingdom Sign Zero-Tariff Agreement on Medicines.
The UK and US have signed a important bilateral deal that will guarantee no tariffs on British drug products going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase funding on medicines through the public health system. This commitment ensures that tariffs on these key exports will stay at nothing for a duration of three years.
This development is in response to previous threats to significantly raise import taxes on patented pharmaceutical imports, with increases mentioned up to double the cost.
"This arrangement with the Britain bolsters the worldwide climate for new treatments and establishes much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Economic Importance
Medicines are one of the UK's largest export categories to the United States, which is by far the largest market for leading companies like GSK and AstraZeneca.
Statistics show that in the year prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This value represented 17.4% of British export trade in that period.
"This agreement protects work, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The pact entails several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double overall NHS spending on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Recent Tensions
This agreement follows a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were intensified by claims that American patients were charged significantly more for the same drugs than people in the other developed nations.
In recent months, several major manufacturing plans in the UK have been paused or abandoned, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the past decade.
